Loading
A phase 1/2 trial of LAM561 in glioma & glioblastoma, run by Laminar Pharmaceuticals, now recruiting.
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04299191 by Laminar Pharmaceuticals, with 28 participants planned, started 2020-09-01 and due to reach its primary completion in 2026-10. Interventions recorded: LAM561.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Laminar Pharmaceuticals, LAM561, Glioma & glioblastoma.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/